396 research outputs found
Imaging for prostate cancer recurrence
No full textContext: Correct identification of metastatic sites in recurrent prostate cancer (PCa) is of crucial importance because it leads to further treatment decisions. Objective: To provide an overview on current imaging procedures and their performance in recurrent PCa. Evidence acquisition: Medline search via PubMed was performed with the keywords imaging, recurrent, and prostate cancer as well as more detailed searches including the keywords bone scan, bone scintigraphy, computed tomography, magnetic resonance imaging, positron emission tomography, PET, choline, FDG, prostate-specific membrane antigen, and PSMA, with emphasis on recent literature from 2010 to the present. Non-English published literature was excluded. Abstracts and full-text articles were reviewed and assessed for relevant content. Evidence synthesis: In diagnostic imaging and particularly with newer technologies like positron emission tomography (PET), a profound lack of prospectively designed studies in recurrent PCa has to be noted. In most studies histologic validation has only been performed in a subset of patient cohorts. Heterogeneity of included patient cohorts, lack of standardized assessment, as well as diverging end points, hamper systematic comparison of different image modalities. Thus evidence for currently used imaging in recurrent PCa is only presented descriptively. Conclusions: Computed tomography and magnetic resonance imaging (MRI) as well as bone scintigraphy still represent the standard imaging for recurrent PCa; however, particularly for detection of local recurrence, multiparametric MRI is a valuable imaging modality. PET using choline and particularly tracers against prostate-specific membrane antigen might improve visualization of metastatic lesions. These findings need to be validated in prospective trials. Patient summary: Imaging of recurrent prostate cancer (PCa) is important to guide further treatment. Computed tomography, magnetic resonance imaging, and bone scintigraphy represent the current standard. Positron emission tomography, especially with cancer-specific tracers, might improve imaging of recurrent PCa in the future. Standard imaging for recurrent prostate cancer includes computed tomography, scintigraphy, and magnetic resonance imaging (MRI). Multiparametric MRI can differentiate local recurrence from residual benign tissue. Positron emission tomography using choline, and particularly tracers against prostate-specific membrane antigen, might improve visualization of metastatic lesions. Validation in prospective trials is required
Business transfer success factors
No full textAuthor Michael EiberMasterarbeit Universität Linz 2023Arbeit auf den öffentlichen PCs in den Bibliotheken der JKU+Medizin abrufba
Business transfer success factors
No full textAuthor Michael EiberMasterarbeit Universität Linz 2023Arbeit auf den öffentlichen PCs in den Bibliotheken der JKU+Medizin abrufba
Contribution of complex stapes motion to cochlea activation
No full textClassic theories of hearing have considered only a translational component (piston-like component) of the stapes motion as being the effective stimulus for cochlear activation and thus the sensation of hearing. Our previous study [Huber, A.M., Sequeira, D., Breuninger, C., Eiber, A., 2008. The effects of complex stapes motion on the response of the cochlea. Otol. Neurotol. 29: 1187–1192.] qualitatively showed that rotational components around the long and short axes of the footplate (rocking-like components) lead to cochlear activation as well. In this study, the contribution of the piston-like and rocking-like components of the stapes motion to cochlea activation was quantitatively investigated with measurements in live guinea pigs and a related mathematical description. The isolated stapes in anesthetized guinea pigs was stimulated by a three-axis piezoelectric actuator, and 3-D motions of the stapes and compound action potential (CAP) of the cochlea were measured simultaneously. The measured values were used to fit a hypothesis of the CAP as a linear combination of the logarithms of the piston-like and rocking-like components. Both the piston-like and rocking-like components activate cochlear responses when they exceed certain thresholds. These thresholds as well as the relation between CAP and intensity of the motion component were different for piston-like and rocking-like components. The threshold was found to be higher and the sensitivity lower for the rocking-like component than the corresponding values for the piston-like component. The influence of the rocking-like component was secondary in cases of piston-dominant motions of the stapes although it may become significant for low amplitudes of the piston-like component
Identification of PCWG3 Target Populations Is More Accurate and Reproducible with PSMA PET Than with Conventional Imaging: A Multicenter Retrospective Study.
No full textProstate-specific membrane antigen (PSMA)-ligand PET is potentially useful for screening of castration-resistant prostate cancer (CRPC) clinical trial target populations. We investigated the impact of PSMA PET on Prostate Cancer Clinical Trials Working Group 3 (PCWG3) clinical subtype classification when compared with conventional imaging (CI). Methods: A multicenter retrospective study enrolled patients who had undergone PSMA PET for CRPC, had prostate-specific antigen values of at least 1 ng/mL, and had undergone CI-that is, CT plus bone scanning or whole-body MRI. The clinical PCWG3 subtype was determined for PET versus CI by 3 masked readers. Results: Sixty-seven patients were included, and PSMA PET led to up-staging in 15% (10/67) of patients; of these, 6 of 10 (60%) had nonmetastatic CRPC on CI. PSMA PET resulted in down-staging in 15% (10/67) of patients. Agreement for PET versus CI PCWG3 clinical subtypes was 0.81 versus 0.51, 0.74 versus 0.47, 0.95 versus 0.72, or 0.59 versus 0.66 for local, nodal, bone, or visceral disease, respectively. Conclusion: Despite 70% concordance with CI, PSMA PET demonstrated superior reproducibility and accuracy especially for non-metastatic CRPC and should be implemented in future clinical trial entry procedures
What is the best PET target for early biochemical recurrence of prostate cancer?–Authors’ reply
No full textTechnologies for image-guided surgery for managing lymphatic metastases in prostate cancer
No full textOne of the challenges for the surgical management of prostate cancer is the lymphatic spread of metastases. Lymph node metastases vary in size (micrometastases (2 mm)), and their interactions with the lymphatic environment differ (whether they are hypoxic or connected to blood flow). Thus, devising a universal imaging system and an image-guided surgical approach that supports the resection of all affected lymph nodes is difficult. Two complementary approaches to identifying affected lymph nodes have been described as alternatives to performing a traditional pelvic lymph node dissection: lymphatic mapping using radioguidance (the most widely applied modality), fluorescence guidance, integrated hybrid radioguidance and fluorescence guidance or magnetic guidance; and surgery guided by radiolabelled prostate-specific membrane antigen. Careful patient selection using preoperative imaging seems to be a crucial aspect in determining whether one of the individual image-guided surgery procedures alone would be optimal or whether a combination would be considered to be the most desirable course of action. The successful implementation and dissemination of both lymph-node-targeted and disease-targeted procedures are very much reliant on ongoing technical developments in the field and their standardization and interpretation. However, when these innovative surgical procedures are fully refined, evaluation of their influence on oncological outcome is imperative.Imaging- and therapeutic targets in neoplastic and musculoskeletal inflammatory diseas
Evaluation of self-esteem in anorexia and bulimia nervosa : comparative studies
No full textThe study is aimed at an attempt to evaluate self-esteem in French and Polish populations with anorexia and bulimia nervosa. The author compared the already existing stu-dies (Eiber et al. 2003) to the results of her research in France and in Poland. The study posed the question whether or not there are differences within self-esteem between groups of patients with anorexia and bulimia nervosa of the same and different nationality, and whether or not there are differences within scores of self-esteem between groups with eating disorders and healthy groups. The studies involved 46 French and 60 Polish patients with eating disorders. The control group consisted of 57 French and 60 Polish healthy students. The Self-Esteem Inventory (SEI) of Coopersmith (1984) was applied in the present study. The results revealed significant differences between the French and Polish groups with eating disorders and between these groups and the control groups. The Polish patients with AN show a significantly higher social self-esteem as compared to the French anorexic patients tested by Eiber et al., but at the same time they show a lower score on the lie scale. As compared to French bulimic patients tested by Eiber et al., Polish patients show a significantly higher social self-esteem but they show lower familial self-esteem. As compared to control groups, the lower self-esteem in the French and Polish patients with eating disorders was observable in all aspects: general, total, social, familial and school. Lower self-esteem is an important factor in the psychopathology of adolescent anorexic and bulimic Polish and French females patients. Key words: self-esteem, anorexia nervosa, bulimia nervosa, Poland, Franc
Potential impact of 68Ga-PSMA-11 PET/CT on the planning of definitive radiation therapy for prostate cancer
No full textStandard-of-care imaging for initial staging of prostate cancer (PCa) underestimates disease burden. Prostate-specific membrane antigen (PSMA) PET/CT detects PCa metastasis with superior accuracy, having a potential impact on the planning of definitive radiation therapy (RT) for nonmetastatic PCa. Our objectives were to determine how often definitive RT planning based on standard target volumes covers 68Ga-PSMA-11 PET/CT-defined disease and to assess the potential impact of 68Ga-PSMA-11 PET/CT on definitive RT planning. Methods: This was a post hoc analysis of an intention-totreat population of 73 patients with localized PCa without prior local therapy who underwent 68Ga-PSMA PET/CT for initial staging as part of an investigational new drug trial. Eleven of the 73 were intermediate- risk (15%), 33 were high-risk (45%), 22 were very-highrisk (30%), and 7 were N1 (9.5%). Clinical target volumes (CTVs), which included the prostate, seminal vesicles, and (in accord with the Radiation Therapy Oncology Group consensus guidelines) pelvic lymph nodes (LNs), were contoured on the CT portion of the PET/CT images by a radiation oncologist masked to the PET findings. 68Ga-PSMA-11 PET/CT images were analyzed by a nuclear medicine physician. 68Ga-PSMA-11-positive lesions not covered by planning volumes based on the CTVs were considered to have a major potential impact on treatment planning. Results: All patients had one or more 68Ga-PSMA-11-positive primary prostate lesions. Twenty-five (34%) and 7 (9.5%) of the 73 patients had 68Ga-PSMA- 11-positive pelvic LN and distant metastases, respectively. The sites of LN metastases in decreasing order of frequency were external iliac (20.5%), common iliac (13.5%), internal iliac (12.5%) obturator (12.5%), perirectal (4%), abdominal (4%), upper diaphragm (4%), and presacral (1.5%). The median size of the LN lesions was 6 mm (range, 4-24 mm). RT planning based on the CTVs covered 69 (94.5%) of the 73 primary lesions and 20 (80%) of the 25 pelvic LN lesions, on a per-patient analysis. Conclusion: 68Ga-PSMA-11 PET/CT had a major impact on intended definitive RT planning for PCa in 12 (16.5%) of the 73 patients whose RT fields covered the prostate, seminal vesicles, and pelvic LNs and in 25 (37%) of the 66 patients whose RT fields covered the prostate and seminal vesicles but not the pelvic LNs
68 Ga-PSMA-11 Positron Emission Tomography Detects Residual Prostate Cancer After Prostatectomy in a Multicenter Retrospective Study
No full textPurpose: Prostate specific antigen persistence after radical prostatectomy is associated with adverse outcomes in patients with prostate cancer. We sought to define regions at risk for residual disease as well as the accuracy of prostate specific membrane antigen ligand positron emission tomography in patients with prostate specific antigen persistence.
Materials and methods: At 6 participating centers a total of 191 patients who underwent 68Ga-prostate specific membrane antigen-11 positron emission tomography/computerized tomography or positron emission tomography/magnetic resonance imaging for persistently elevated postoperative prostate specific antigen (0.1 ng/ml or greater) were retrospectively included in study. The detection rate and the positive predictive value were determined. In 33 patients with additional prostate specific membrane antigen ligand positron emission tomography before prostatectomy we also determined the rate of positron emission tomography based persistence and recurrence.
Results: Prostate specific membrane antigen ligand positron emission tomography localized prostate cancer in 130 of 191 patients (68%) with prostate specific antigen persistence at a median prostate specific antigen of 1.1 ng/ml. The detection rate significantly increased with prostate specific antigen (p <0.001). Regarding prostate specific membrane antigen positron emission tomography/computerized tomography only 61 of 173 patients (35%) had disease confined to the pelvis while 57 of 173 (33%) had distant lesions. The most frequently affected nodal regions were the obturator in 42% and the presacral/mesorectal region in 40%. In 15 of the 33 patients (45%) with prostate specific membrane antigen ligand positron emission tomography before and after surgery at least 1 lesion was detected at baseline (positron emission tomography persistence), 8 (24%) had new lesions (positron emission tomography recurrence) and 10 (30%) had negative positron emission tomography findings. The positive predictive value of prostate specific membrane antigen ligand positron emission tomography was 91%. Systemic therapy initiation was significantly associated with distant lesions on prostate specific membrane antigen ligand positron emission tomography.
Conclusions: Prostate specific membrane antigen ligand positron emission tomography localized prostate cancer in more than two-thirds of patients with high risk features and prostate specific antigen persistence after prostatectomy. Obturator and presacral/mesorectal nodes are at high risk for persistent metastasis
- …
